Cooperation between Pik3ca and p53 mutations in mouse mammary tumor formation

Jessica R Adams1, Keli Xu, Jeff C Liu

  • 1Program in Developmental and Stem Cell Biology, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.

Cancer Research
|February 18, 2011
PubMed

Insights

A new mouse model reveals that PIK3CA mutations drive diverse breast cancers. Cooperation between PIK3CA and p53 mutations accelerates tumor formation and alters cancer types.

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • PIK3CA mutations are frequent drivers in human breast cancer.
  • Understanding PIK3CA's role requires robust preclinical models.

Purpose of the Study:

  • To develop and characterize a mouse model for PIK3CA-driven breast cancer.
  • To investigate the genetic interaction between PIK3CA and p53 in mammary tumor development.

Main Methods:

  • Utilized the ROSA26 (R26) knock-in system for inducible Pik3ca activation.
  • Crossed Pik3ca knock-in mice with MMTV-Cre transgenics for mammary-specific expression.
  • Assessed tumor development and characterized tumor types in genetically modified mice, including those with p53 mutations.

Main Results:

  • R26-Pik3ca(H1047R);MMTV-Cre mice developed mammary tumors (adenosquamous carcinoma, adenomyoepithelioma), as well as lymphoid and skin malignancies.
  • Combined Pik3ca(H1047R) and p53 loss-of-function mutations accelerated tumor formation and led to decreased survival.
  • Double-mutant mice exhibited distinct mammary tumor spectra, including adenosquamous carcinoma and spindle cell/EMT, compared to single mutants.

Conclusions:

  • PIK3CA oncogenic variants can induce a diverse spectrum of mammary tumors in mice.
  • PIK3CA cooperates with p53 mutations, altering mammary tumor formation and progression.
  • This model provides insights into the cooperative roles of frequently mutated genes in breast cancer.

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Mouse Models of Cancer Study02:43

Mouse Models of Cancer Study

Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...